FogPharma’s Post

As #organoids and #tumoroids become a more popular model in research, there is an increasing need for models, assays, and workflows to study patient-derived samples. In this webinar, Dr. Margarite Matossian presented the Burow Lab translational research project which addressed therapeutics and drug resistance in triple negative breast cancer (#TNBC) using patient-derived organoids in the #pumasystem.     View the full webinar:  https://lnkd.in/dCJpJFN    #3Dcellassay #flowchips #microfluidic #cancerresearch #lifescienceresearch #precisiononcology #3dcellculture #biotech #preclinicalresearch #drugdiscovery #biomarkers #biomarkerdrugdiscovery #cellbasedassay 

Comprehensive characterization of cell surface tumor-associated antigens (TAAs) is critically important in the development of #antibodydrug conjugates, as efficacy and safety depend on the binding optimization of an ADC to these targets. See how Sapient's /𝐃𝐞𝐞𝐩/ 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 proteomics approach measures 1,000 cell surface proteins to identify TAAs that are differentially and abundantly expressed on tumors, including novel TAAs for ADC targeting: https://lnkd.in/gi-5hCaB #ADCs #oncology #cancertherapeutics #oncologybiomarkers

Oniria Therapeutics receives €964,000 from the Ministry of Science and Innovation of Spain and European Union, through the #NextGenerationEU program, for a public-private collaboration project to develop a TET2 drug activator for the treatment of #melanoma. TET2, a master epigenetic enzyme, is the Achilles heel of persistent tumour cells, and Oniria's new drugs focus on attacking this vulnerability. The project will be carried out in collaboration with the Dr Hector G Palmer's Lab at Vall d'Hebron Institute of Oncology (VHIO) and Dr Juan Angel Recio PhD's Lab at Vall d’Hebron Institute of Research (VHIR) - Vall d'Hebron Institut de Recerca. Let's start 2024 as we mean to go on! #CancerPersistence #PrecisionOncology #oncology #cancer #biotech #innovation #DrugDiscovery

Advanced preclinical cancer models have the potential to enhance translational success. 3D cell cultures, for example, more accurately represent cancer complexities than 2D cell lines, which lack cell heterogeneity, differentiated phenotypes, ECM architecture and drug resistance seen in vivo.[1] The BarneyOI Cancer Model Database features matched PDX in vivo and PDX-derived in vitro models (breast model featured here as an example) that can help reduce variability between early and definitive preclinical studies and may lead to better translation of preclinical data in the clinic. View more details or get access to the model now: https://hubs.la/Q024cgws0. Reference [1]: Gencoglu MF et al. ACS Biomater Sci Eng. (2018). #TumorModels #CancerResearch #BreastCancer #3DModels #CertaintyisPriceless

Interleukin-18 (IL-18), a proinflammatory cytokine, can activate several types of immune cells that are important for fighting cancer. However, its efficacy is limited by the rapid upregulation of the IL-18 binding protein, which neutralizes and inhibits its signaling. We’re engineering an enhanced variant aimed at improved potency: https://bit.ly/3V0qhBr #biotechnology #oncology #drugdevelopment #innovation #immunooncology

Purdue University innovations are saving lives, and another exciting license for #cancer research has been announced! Australian #biotech company Ferronova is joining forces with Purdue Research Foundation, combining patented technologies that will be applied in targeted radiotherapy of cancers such as glioblastoma, prostate cancer, and pancreatic cancer. Led by Dr. Philip Low, the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor for Chemistry at the Purdue University College of Science's Department of Chemistry, #Purdue researchers developed an FAP inhibitor that inhibits a pathway associated with the formation of cancer-associated fibroblasts (CAFs), cells that regulate tumor growth. Ferronova's vision is to give everyone diagnosed with cancer their best chance to become cancer-free, and this license with Purdue Innovates is another step towards that goal. Read more: https://ow.ly/4yAZ50PCRUP

Purdue University innovations are saving lives, and another exciting license for #cancer research has been announced! Australian #biotech company Ferronova is joining forces with Purdue Research Foundation, combining patented technologies that will be applied in targeted radiotherapy of cancers such as glioblastoma, prostate cancer, and pancreatic cancer. Led by Dr. Philip Low, the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor for Chemistry at the Purdue University College of Science's Department of Chemistry, #Purdue researchers developed an FAP inhibitor that inhibits a pathway associated with the formation of cancer-associated fibroblasts (CAFs), cells that regulate tumor growth. Ferronova's vision is to give everyone diagnosed with cancer their best chance to become cancer-free, and this license with Purdue Innovates is another step towards that goal. Read more: https://ow.ly/4yAZ50PCRUP